Compare Amgen, Inc. (AMGN) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs iShares MSCI India ETF — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while iShares MSCI India ETF trades at $48.74. The key difference: Amgen, Inc. pays a 2.77% dividend while iShares MSCI India ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | INDA | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $388.16 | $55.29 |
52-Week Low | $271.18 | $45.42 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
INDA, the iShares MSCI India ETF, trades at $49.30 with a slight 0.57% daily gain amid a predominantly bearish technical outlook. The ETF faces mixed sentiment with India's strong 7.8% GDP growth (CNBC, 2026-06-05) contrasting with sectoral challenges in IT and clean energy. Technical indicators show neutral oscillators but bearish moving averages, with all support and resistance levels clustered around $49.
The outlook remains cautious due to macroeconomic risks from Middle East conflicts and domestic sector pressures. However, India's position as the fastest-growing large economy and analyst price targets suggesting upside potential (Seeking Alpha, 2026-06-03) offer long-term opportunities amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
